We use our own and third party cookies to offer you our services, customize and analyze your browsing and show you advertising related to your preferences. By continuing to browse, we consider that you accept its use. You can change the settings and get more information in the
The Omicron variant of the coronavirus causing COVID-19 first appeared in South Africa in November 2021.
This variant now represents 90% of coronavirus infections in South Africa and has spread to more than 100 countries. After arriving in a country, the Omicron variant is expected to replace the Delta variant in about 3-4 weeks.
This variant has changes or mutations in its DNA with respect to previous coronavirus variants. Some of these mutations have allowed it to remodel the Spike protein (S) to be more efficient at infecting cells through the AC-2 receptor, a protein on the plasma membrane of human cells.
One of the main differences between this and previous variants is its contagiousness. The transmission rate of the Omicron variant is the highest of the variants found so far. The R number (the average number of people an infected person passes the disease on to) for this variant is calculated to be 10. As well as infecting unvaccinated people, this variant also infects a significant number of people already vaccinated.
This variant has a number of changes, also called mutations, in its external structure and DNA, compared with previous variants. Some of the advantages these mutations provide for the virus are:
More efficient entry into human cells (of the respiratory system). This gives it greater infectivity.
It replicates more in the upper respiratory tract, that is, in the bronchi rather than the lungs. This causes a higher viral load in the upper respiratory tract which makes infected people more contagious.
The methods used so far to diagnose coronavirus variants are as effective in diagnosing the Omicron variant.
Commercial antigen tests available in chemists detect the N protein of the nucleus and not the S, which is what the mutations have. Therefore, these tests detect all the variants, as they all have the N protein.
The PCR test amplifies coronavirus genes common to all variants, including those of the Omicron variant which have not mutated, so persons infected with the Omicron variant will still test positive. The only exception is the Thermo Fisher TaqPath Kit. This detects the coronavirus S protein, which the Omicron variant does not have; so the test cannot detect this variant and will give a negative result for it.
The PCR test amplifies or detects more than one coronavirus gene and there are more than 40 different types of PCR tests. Only 8 of these detect the gene that provides the information to make the S protein, and one of these is the Thermo Fisher TaqPath Kit, which detects 3 genes: ORF1AB and the S and N (of the nucleus). Therefore, if this PCR test does not detect the S gene but does find the other two genes, then this is indicative of the Omicron variant; this variant accumulates so many mutations in the S gene that it is not detectable. Therefore, this test can detect this new variant.
The Omicron variant has a faster infection rate. The incubation period (the time from infection to when the person shows symptoms) is much shorter than for other variants: 2 days instead of 4-6 days.
Some of the different symptoms of this variant with respect to previous ones are:
Itching and discomfort in the throat.
It usually does not cause loss of smell or taste.
The fact that the virus grows more in the bronchi instead of the lungs makes it a milder disease; with symptoms more akin to bronchitis than pneumonia.
The probability of hospitalisation is much lower than with other variants.
There are 3 main antiviral treatments shown to be effective against the Omicron variant. These are Remdesivir, approved in Spain, Molnupiravir and Nirmatrevir. The latter two are in the process of being approved by the European Medicines Agency (EMA).
Most monoclonal antibodies (with the exception of Sotrovimab) and the plasma of already immunised people are not very effective in treating patients infected with this coronavirus variant.
The effectiveness of complete vaccination (two doses) against COVID-19 decreases markedly at 6 months, and has been shown to protect little from infection by the Omicron variant, as antibody levels are very low after this time.
However, the cellular immunity produced probably protects people from severe disease. That is why a third dose should be given to the elderly and those with comorbidities. 2-4 weeks after a 3rd dose (of mRNA vaccines, i.e. Pfizer or Moderna), immunity is very high, its efficiency increases up to 60-70%. However, preliminary data from the UK say that protection is significantly reduced after 3 months and it is not known whether farther booster doses will be needed later.
As a result of these investigations, the need to produce a new generation of vaccines containing a combination of the variants that have already appeared has become evident. Fortunately, there are already over 300 research projects working on COVID-19 vaccine updates, including the project carried out in Catalonia with Hipra.
We are sorry, we are working to improve PortalCLÍNIC. Help us become better, tell us why
Thanks for your help!
An error has occurred and we were unable to send your opinion, please try again later.
Substantiated information by:
Antoni TrillaHead of the Department of Preventive Medicine and Epidemiology
Eduard Vieta PascualPsychiatristPsychiatry and Psychology Head of Department
Gema Maria Lledó IbáñezMédico internistaServicio de enfermedades autoinmunes
Jacobo Sellarés TorresPulmonologistPneumology Department
Josep M. Miró Meda
Josep Maria PeriClinical psychologist
Maica RubinatSpecialist in Sports MedicineGeneral Secretary for Sport and Physical Activity of the Generalitat de Catalunya
Mariona ViolanSpecialist in Sports MedicineGeneral Secretary for Sport and Physical Activity of the Generalitat de Catalunya
Published: 12 March 2020
Updated: 12 March 2020
The donations that can be done through this webpage are exclusively for the benefit of Hospital Clínic of Barcelona through Fundació Clínic per a la Recerca Biomèdica and not for BBVA Foundation, entity that collaborates with the project of PortalClínic.
Receive the latest updates related to this content.
Thank you for subscribing!
If this is the first time you subscribe you will receive a confirmation email, check your inbox
An error occurred and we were unable to send your data, please try again later.